A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Clinical trial NCT06720896 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06720896
- Sponsor
- Aperta Biosciences, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-01
- Primary completion
- 2026-06-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.